• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿毒症毒素和氧化应激在慢性肾脏病-矿物质和骨异常发展中的作用。

Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder.

机构信息

Division of Nephrology, Endocrinology, and Metabolism, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

出版信息

J Ren Nutr. 2012 Jan;22(1):98-101. doi: 10.1053/j.jrn.2011.10.031.

DOI:10.1053/j.jrn.2011.10.031
PMID:22200424
Abstract

The kidney plays an important role in the regulation of mineral metabolism. As kidney function declines, there is a progressive deterioration in mineral homeostasis, along with various abnormalities, including bone disease and vascular calcification, which has recently been named as "Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)." Although the precise mechanisms of this systemic disorder remain to be elucidated, accumulating evidence suggest that uremic toxins contribute substantially to the development of CKD-MBD, partly through evoking oxidative stress in the bone and cardiovascular systems. This brief review summarizes recent work on the role of uremic toxins and oxidative stress in the development of CKD-MBD.

摘要

肾脏在矿物质代谢调节中起着重要作用。随着肾功能下降,矿物质内环境稳态逐渐恶化,同时出现各种异常,包括骨骼疾病和血管钙化,最近被命名为“慢性肾脏病-矿物质和骨代谢异常(CKD-MBD)”。尽管这种全身性疾病的确切机制仍有待阐明,但越来越多的证据表明,尿毒症毒素在 CKD-MBD 的发展中起重要作用,部分是通过在骨骼和心血管系统中引发氧化应激。这篇简要综述总结了尿毒症毒素和氧化应激在 CKD-MBD 发展中的作用的最新研究进展。

相似文献

1
Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder.尿毒症毒素和氧化应激在慢性肾脏病-矿物质和骨异常发展中的作用。
J Ren Nutr. 2012 Jan;22(1):98-101. doi: 10.1053/j.jrn.2011.10.031.
2
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].[慢性肾脏病-矿物质和骨异常(CKD-MBD)。甲状旁腺干预:尿毒症性继发性甲状旁腺功能亢进患者管理的最后一环]
Clin Calcium. 2010 Jul;20(7):1104-10.
3
[Kidney and bone update : the 5-year history and future of CKD-MBD. Vascular calcification in CKD patients].[肾脏与骨骼最新进展:慢性肾脏病-矿物质和骨异常的5年历程与未来。慢性肾脏病患者的血管钙化]
Clin Calcium. 2012 Jul;22(7):993-9.
4
Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.肠道微生物群产生的尿毒症毒素对骨骼的影响:慢性肾脏病概述
Ther Apher Dial. 2015 Oct;19(5):436-40. doi: 10.1111/1744-9987.12307. Epub 2015 May 5.
5
Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.透析患者接受司维拉姆治疗后的血清心血管和死亡风险预测因子:一项前瞻性研究。
Nephrol Dial Transplant. 2010 Aug;25(8):2672-9. doi: 10.1093/ndt/gfq053. Epub 2010 Feb 18.
6
Use of sevelamer in chronic kidney disease: beyond phosphorus control.使用司维拉姆治疗慢性肾脏病:不仅仅是控制磷。
Nefrologia. 2015;35(2):207-17. doi: 10.1016/j.nefro.2015.05.022. Epub 2015 Jun 23.
7
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.慢性肾脏病中骨矿物质代谢紊乱的整体药理学管理(第一部分):从治疗磷酸盐失衡到控制甲状旁腺激素和预防心血管钙化进展。
Expert Opin Pharmacother. 2016 Jun;17(9):1247-58. doi: 10.1080/14656566.2016.1182155. Epub 2016 May 13.
8
Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?慢性肾脏病-矿物质和骨异常中的实验室异常:疾病的标志物、预测指标还是介质?
Semin Nephrol. 2014 Mar;34(2):151-63. doi: 10.1016/j.semnephrol.2014.02.007. Epub 2014 Feb 18.
9
Chronic kidney disease--mineral and bone disorder: a complex scenario.慢性肾脏病-矿物质和骨异常:复杂的情况。
Nefrologia. 2011;31(5):514-9. doi: 10.3265/Nefrologia.pre2011.Jun.10926.
10
Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.碳酸司维拉姆治疗可逆转慢性肾脏病中的动力缺乏性骨病并减少血管钙化。
J Am Soc Nephrol. 2007 Jan;18(1):122-30. doi: 10.1681/ASN.2006050490. Epub 2006 Dec 20.

引用本文的文献

1
Lactobacillus johnsonii Generates Cyclo(pro-trp) and Promotes Intestinal Ca Absorption to Alleviate CKD-SHPT.约氏乳杆菌产生环(脯氨酸-色氨酸)并促进肠道钙吸收以减轻慢性肾脏病继发性甲状旁腺功能亢进。
Adv Sci (Weinh). 2025 Apr;12(16):e2414678. doi: 10.1002/advs.202414678. Epub 2025 Jan 31.
2
Dose-dependent exposure to indoxyl sulfate alters AHR signaling, sirtuins gene expression, oxidative DNA damage, and bone mineral status in rats.硫酸吲哚酚的剂量依赖性暴露改变了大鼠的 AHR 信号转导、沉默调节蛋白基因表达、氧化 DNA 损伤和骨矿物质状态。
Sci Rep. 2024 Jan 31;14(1):2583. doi: 10.1038/s41598-024-53164-3.
3
Tryptophan Metabolites Target Transmembrane and Immunoglobulin Domain-Containing 1 Signaling to Augment Renal Tubular Injury.
色氨酸代谢物靶向跨膜和免疫球蛋白结构域包含蛋白 1 信号转导以增强肾小管损伤。
Am J Pathol. 2023 Oct;193(10):1501-1516. doi: 10.1016/j.ajpath.2023.06.018. Epub 2023 Sep 5.
4
Supplemented Low-Protein Diet May Delay the Need for Preemptive Kidney Transplantation: A Nationwide Population-Based Cohort Study.补充低蛋白饮食可能延缓预防性肾移植的需求:一项全国性基于人群的队列研究。
Nutrients. 2021 Aug 28;13(9):3002. doi: 10.3390/nu13093002.
5
Does a Supplemental Low-Protein Diet Decrease Mortality and Adverse Events After Commencing Dialysis? A Nationwide Cohort Study.补充低蛋白饮食是否能降低开始透析后的死亡率和不良事件?一项全国性队列研究。
Nutrients. 2018 Aug 8;10(8):1035. doi: 10.3390/nu10081035.
6
Role of Gut-derived Uremic Toxins on Oxidative Stress and Inflammation in Patients with Chronic Kidney Disease.肠道源性尿毒症毒素在慢性肾脏病患者氧化应激和炎症中的作用
Indian J Nephrol. 2017 Sep-Oct;27(5):359-364. doi: 10.4103/ijn.IJN_71_17.
7
Association of GSTO1 and GSTO2 Polymorphism with Risk of End-Stage Renal Disease Development and Patient Survival.谷胱甘肽S-转移酶O1(GSTO1)和谷胱甘肽S-转移酶O2(GSTO2)基因多态性与终末期肾病发生风险及患者生存率的关联
J Med Biochem. 2016 Sep;35(3):302-311. doi: 10.1515/jomb-2016-0009. Epub 2016 Jul 6.
8
Oxidative Stress as Estimated by Gamma-Glutamyl Transferase Levels Amplifies the Alkaline Phosphatase-Dependent Risk for Mortality in ESKD Patients on Dialysis.通过γ-谷氨酰转移酶水平评估的氧化应激会增加接受透析的终末期肾病(ESKD)患者因碱性磷酸酶而导致的死亡风险。
Oxid Med Cell Longev. 2016;2016:8490643. doi: 10.1155/2016/8490643. Epub 2016 Jul 25.
9
Chronic kidney disease and bone metabolism.慢性肾脏病与骨代谢
J Bone Miner Metab. 2015 May;33(3):245-52. doi: 10.1007/s00774-014-0639-x. Epub 2015 Feb 5.
10
Evaluation of assays for measurement of serum (anti)oxidants in hemodialysis patients.血液透析患者血清(抗)氧化剂测量方法的评估
Biomed Res Int. 2014;2014:843157. doi: 10.1155/2014/843157. Epub 2014 May 19.